@article{e7ab371b7b454f6095bdeaf4a6658564,
title = "Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012",
abstract = "Background. The HIV Network for Prevention Trials (HIVNET) 012 trial showed that NVP resistance (NVPR) emerged in some women and children after the administration of single-dose nevirapine (SD-NVP). We tested whether K103N-containing human immunodeficiency virus (HIV)-1 variants persisted in women and infants 1 year or more after the administration of SD-NVP. Methods. We analyzed samples from 9 women and 5 infants in HIVNET 012 who had NVPR 6-8 weeks after the administration of SD-NVP. Samples were analyzed with the ViroSeq system and with 2 sensitive resistance assays, LigAmp and TyHRT. Results. ViroSeq detected the K103N mutation in 8 of 9 women and in 2 of 5 infants. LigAmp detected the K103N mutation at low levels in 8 of 9 women and in 4 of 5 infants. K103N was not detected by ViroSeq 12-24 months after the administration of SD-NVP but was detected by LigAmp in 3 of 9 women and in 1 of 5 infants. K103N was also detected in those samples by use of the TyHRT assay. Conclusions. K103N-containing variants persist in some women and infants for 1 year or more after the administration of SD-NVP. Sensitive resistance assays may provide new insight into the impact of antiretroviral drug exposure on HIV-1 evolution.",
author = "Tamara Flys and Nissley, {Dwight V.} and Claasen, {Cassidy W.} and Dana Jones and Chanjuan Shi and Guay, {Laura A.} and Philippa Musoke and Francis Mmiro and Strathern, {Jeffrey N.} and Jackson, {J. Brooks} and Eshleman, {James R.} and Eshleman, {Susan H.}",
note = "Funding Information: Financial support: HIV Network for Prevention Trials, sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH), and the Department of Health and Human Services (DHHS) through contracts with Family Health International (N01-AI-35173), Fred Hutchinson Cancer Research Center (N01-AI-45200), and Makerere University (NOI-AI-35173-417); HIV Prevention Trials Network, sponsored by the NIAID, the National Institutes of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the Office of AIDS Research of the NIH, DHHS (grants U01-AI-46745 and U01-AI-48054); Adult AIDS Clinical Trials Groups, sponsored by the NIH, Division of AIDS, NIAID (grant U01-AI-38858); NIH (grant R01-HD042965-01 to S.H.E.); National Cancer Institute, NIH (grant R01 CA81439 to J.R.E. and contract NO1-CO-12400); Maryland Cigarette Restitution Fund (grant to J.R.E.); Canadian Institute of Health Research (fellowship to C.S.).",
year = "2005",
month = jul,
day = "1",
doi = "10.1086/430742",
language = "English (US)",
volume = "192",
pages = "24--29",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",
}